FourThought Financial Partners LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

FourThought Financial Partners LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,237 shares of the company’s stock after purchasing an additional 570 shares during the period. FourThought Financial Partners LLC’s holdings in Zoetis were worth $3,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of ZTS. Blue Bell Private Wealth Management LLC grew its position in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its holdings in Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in Zoetis in the 3rd quarter valued at about $35,000. First Financial Corp IN increased its position in shares of Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the period. Finally, FinTrust Capital Advisors LLC raised its stake in shares of Zoetis by 42.1% during the third quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after acquiring an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ZTS. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group boosted their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Finally, Piper Sandler restated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $216.13.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 2,209 shares of company stock valued at $371,293 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Down 0.1 %

NYSE:ZTS traded down $0.16 during mid-day trading on Friday, hitting $167.07. 3,007,125 shares of the company’s stock traded hands, compared to its average volume of 4,607,073. The company has a fifty day moving average of $168.88 and a 200 day moving average of $178.84. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market capitalization of $76.41 billion, a P/E ratio of 32.19, a P/E/G ratio of 2.62 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. Zoetis’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.31 EPS. On average, analysts forecast that Zoetis Inc. will post 5.78 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.